Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has completed recruitment of 20 patients in the ATLAS-IT-05 trial - a trial evaluating LTX-315, Lytix’s lead drug candidate.
The ATLAS-IT-05 trial is designed to assess the efficacy of LTX-315 in .